← ANALYST RATINGS · TIPRANKS
Artivion (AORT): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $41.87, the highest $45.00, the lowest $38.00. The average is +92.2% from the last price of $21.78.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $23.50 → $24.00+2.1% | Buy | +10.2% | Upgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $21.50 → $22.00+2.3% | Hold | +1.0% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $22.00 → $22.50+2.3% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $21.00 → $21.50+2.4% | Hold | −1.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $22.00 → $22.50+2.3% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $22.00 → $22.50+2.3% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $39.00 → $40.00+2.6% | Buy | +83.7% | Reiterated | 18.08.26on TipRanks 07:05 | +2.7%next day −0.5% · 5 days −8.5% | ↗ |
| Jeffrey Cohen★★★★★★★★★★#11115 · hits 35% · avg −2.9% | Ladenburg Thalmann & Co. | $42.00 → $39.20−6.7% | Buy | +80.0% | Reiterated | 07.08.26on TipRanks 09:20 | +1.5%next day −3.0% · 5 days +7.0% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $45.00 | Buy | +106.6% | Reiterated | 07.08.26on TipRanks 09:15 | +1.5%next day −3.0% · 5 days +7.0% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | $38.00 | Buy | +74.5% | Assigned | 07.08.26on TipRanks 08:20 | +1.5%next day −3.0% · 5 days +7.0% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $45.00 | Buy | +106.6% | Reiterated | 07.08.26on TipRanks 08:15 | +1.5%next day −3.0% · 5 days +7.0% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $44.00 | Buy | +102.0% | Reiterated | 07.08.26on TipRanks 07:16 | +1.5%next day −3.0% · 5 days +7.0% | ↗ |
| Daniel Stauder★★★★★★★★★★#1786 · hits 56% · avg +23.5% | Citizens JMP | $53.00 → $48.00−9.4% | Buy | +120.4% | Reiterated | 08.05.26on TipRanks 21:20 | −6.5%next day −2.8% · 5 days −0.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Artivion
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $41.87 at a price of $22.82 (+83.5%); now: $41.87 at $21.78 (+92.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 13 | 12 | 11 | 4 | 3 |
| Buy | 6 | 4 | 2 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.24 to $0.06). Last quarter: $-0.28.
Sales
Next quarter’s sales estimate — $121M (from $118M to $124M). Last quarter: $126M.
Best top-analyst consensus in the sector · Healthcare
About Artivion
- CEO: James Patrick Mackin
- Employees: 1,800
- 1655 Roberts Boulevard N.W., Kennesaw, GA, 30144, US
- artivion.com
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as
Data from the stock’s TipRanks forecast page, read 118 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗